No Benefit of Rituximab in Primary Central Nervous System Lymphoma Patients: Results of the Randomised Phase III HOVON 105 / ALLG NHL 24 Intergroup Study
Journal article published in 2018 by
J. E. C. Bromberg,
Samar Issa,
Katerina Bakunina,
Monique C. Minnema,
Tatjana Seute,
Marc Durian,
Gavin Cull,
Harry C. Schouten,
Wendy B. C. Stevens,
Josee M. Zijlstra,
Joke W. Baars,
Marcel Nijland,
Kylie D. Mason 
,
Aart Beeker,
Martin J. van den Bent
and other authors.
,
Aart Beeker,
Martin J. van den Bent
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Postprint:
archiving forbidden
Published version:
archiving forbidden
Data provided by 